- Home
- ROOT vs PCRX Comparison
ROOT vs PCRX Comparison
Compare ROOT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- PCRX
- Stock Information
- Founded
- ROOT 2015
- PCRX 2006
- Country
- ROOT United States
- PCRX United States
- Employees
- ROOT N/A
- PCRX N/A
- Industry
- ROOT Property-Casualty Insurers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ROOT Finance
- PCRX Health Care
- Exchange
- ROOT Nasdaq
- PCRX Nasdaq
- Market Cap
- ROOT 1.3B
- PCRX 1.2B
- IPO Year
- ROOT 2020
- PCRX 2011
- Fundamental
- Price
- ROOT $100.21
- PCRX $25.16
- Analyst Decision
- ROOT Buy
- PCRX Buy
- Analyst Count
- ROOT 9
- PCRX 9
- Target Price
- ROOT $58.38
- PCRX $26.22
- AVG Volume (30 Days)
- ROOT 414.9K
- PCRX 805.4K
- Earning Date
- ROOT 02-26-2025
- PCRX 02-27-2025
- Dividend Yield
- ROOT N/A
- PCRX N/A
- EPS Growth
- ROOT N/A
- PCRX N/A
- EPS
- ROOT N/A
- PCRX N/A
- Revenue
- ROOT $1,044,599,999.00
- PCRX $694,957,000.00
- Revenue This Year
- ROOT N/A
- PCRX $5.55
- Revenue Next Year
- ROOT $6.48
- PCRX $5.64
- P/E Ratio
- ROOT N/A
- PCRX N/A
- Revenue Growth
- ROOT 215.11
- PCRX 4.40
- 52 Week Low
- ROOT $13.53
- PCRX $11.16
- 52 Week High
- ROOT $141.23
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- ROOT 46.86
- PCRX 52.48
- Support Level
- ROOT $100.66
- PCRX $25.41
- Resistance Level
- ROOT $141.23
- PCRX $26.89
- Average True Range (ATR)
- ROOT 10.67
- PCRX 1.18
- MACD
- ROOT -1.31
- PCRX -0.36
- Stochastic Oscillator
- ROOT 13.86
- PCRX 4.35
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.